anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
PURPOSE:To obtain the titled material having excellent affinity to gingival tissue and appearance and the free from toxicity to human body, by adding a metal oxide as a coloring component, a metal component as a coloring assistant component and optionally Al2O3 and/or SiO2 as coloring adjuvant to a calcium phosphate composition having a specific Ca/P atomic ratio. CONSTITUTION:(A) 100pts.wt. of a calcium phosphate material produced by mixing a Ca-containing compound such as CaO, CaCO3, etc., with a P-containing compound such as orthophosphoric acid, polyphosphoric acid, etc., at a ratio to give a Ca/P atomic ratio of 0.35-1.7 is compounded with (B) 0.01-5pts.wt. of one or more coloring components selected from oxides of Zn, Fe, Mn, Ce, W, Ti, Ni, Co, Cr or V, (C) 0.1-5pts.wt. (in terms of metal) of a coloring assistant component consisting of a component containing one or more metals selected from Au, Ag and Cu (e.g. auric chloride) and (D) &lt;=10pts.wt. of a optional coloring adjuvant composed of Al2O3 and/or SiO2. The produced mixture is vitrified by melting, molded in the form of desired dental crown, etc., and crystallized to obtain a dental crown, etc., having the color tone of a natural tooth.
PURPOSE:To obtain a new compound excellent in water solubility, having antiallergic activity, anti-inflammatory activity and antioxidizing activity, etc., thus useful for preventing or treating allergic diseases, inflammatory diseases, cataract and ischemic organopathy. CONSTITUTION:The objective compound is expressed by formula I (R is H, OH, methyl or methylene; however, when there is OH at the 17-site of the steroid skeleton, or when R is OH, also including the acylated form or ketone form of the steroid skeleton, respectively) or a salt thereof, e.g. 21-(L-ascorbic acid-2-phosphoryl)dexamethasone sodium salt. This compound of formula I can be obtained by condensation reaction between an adrenocortical steroid of formula II and ascorbic acid-2-phosphoric ester of formula III in the presence of a dehydrating condensation agent (pref. N,N&#39;-dicyclohexylcarbodiimide) in a solvent (pref. pyridine) at room temperature for 1-5hr.
Dimerization and oligomerization of proteins are general biological control mechanisms that contribute to the activation of cell membrane receptors, transcription factors, vesicle fusion proteins, and other classes of intra- and extracellular proteins. We have developed a general procedure for the regulated (inducible) dimerization or oligomerization of intracellular proteins. In principle, any two target proteins can be induced to associate by treating the cells or organisms that harbor them with cell permeable, synthetic ligands. To illustrate the practice of this invention, we have induced: (1) the intracellular aggregation of the cytoplasmic tail of the ζ chain of the T cell receptor (TCR)-CD3 complex thereby leading to signaling and transcription of a reporter gene, (2) the homodimerization of the cytoplasmic tail of the Fas receptor thereby leading to cell-specific apoptosis (programmed cell death) and (3) the heterodimerization of a DNA-binding domain (Gal4) and a transcription-activation domain (VP16) thereby leading to direct transcription of a reporter gene. Regulated intracellular protein association with our cell permeable, synthetic ligands offers new capabilities in biological research and medicine, in particular, in gene therapy. Using gene transfer techniques to introduce our artificial receptors, one can turn on or off the signaling pathways that lead to the overexpression of therapeutic proteins by administering orally active &#34;dimerizers&#34; or &#34;de-dimerizers&#34;, respectively. Since cells from different recipients can be configured to have the pathway overexpress different therapeutic proteins for use in a variety of disorders, the dimerizers have the potential to serve as &#34;universal drugs&#34;. They can also be viewed as cell permeable, organic replacements for therapeutic antisense agents or for proteins that would otherwise require intravenous injection or intracellular expression (e.g., the LDL receptor or the CFTR protein).
FIELD: perfume-cosmetic industry. SUBSTANCE: emulsion &#34;oil-in-water&#34; for cosmetic and dermatological agents has gel-forming agent and thermoplastic hollow swollen particles of polymer or acrylonitrile copolymer providing dispersion of an oily phase in an aqueous gel-like phase. These particles are mainly particles of the swollen copolymer of acrylonitrile and acrylic or styrene monomer and/or vinylidene chloride. Emulsion provides skin and hair care and cleansing and skin making up also. EFFECT: improved quality of emulsion. 20 cl, 1 tbl, 7 ex
FIELD: medicine, pharmacy. SUBSTANCE: invention relates to pharmaceutical preparation used for prophylaxis and treatment of influenza. Preparation ensures to prevent infection propagation. Preparation &#34;Antiagrippin&#34; containing ascorbic acid, rutin, dimedrol and calcium gluconate comprises additionally paracetamol and accessory substances taken in the definite ratio of components. Preparation comprises calcium stearate and starch as accessory substances. EFFECT: prolonged time of storage of preparation. 2 cl, 1 tbl
PURPOSE: To obtain a permanent wave agent composition containing 1,3- propanediol monothioglycolate (PMTG) as a reducing agent and used for imparting waves to hair. CONSTITUTION: This permanent wave agent composition contains 1,3-PMTG alone or its mixture with one or more kinds of other reducing agents. The content of the 1,3-PMTG is 65-100wt.% in the whole reducing agents. When the 1,3-PMTG is mixed with the other reducing agents, the content of the other reducing agents is &lt;=50wt.%. From the viewpoint of the formation of waves on hair, the content of the other reducing agents is referably &lt;=10wt.% based on the 1,3-PMTG. The reducing agent is compounded with an alkali agent, a surfactant, a polyhydric alcohol, and further conventional arbitrary components and subsequently prepared into an (aqueous) solution, an emulsion, a cream, a foaming agent, etc. The permanent wave agent composition acts at a pH not damaging the wave, gives a good waving effect, and does substantially not affect skin.
&lt;P&gt;PROBLEM TO BE SOLVED: To inexpensively provide a composition for oral ingestion, abundantly including ergosterol promoting secretion of adiponectin.  &lt;P&gt;SOLUTION: An adiponectin secretion-promoting composition includes mushrooms containing the ergosterol as an active ingredient. The composition includes the mushrooms in the form of powder or a liquid and one or the plurality of mushrooms selected from the group consisting of Lentinus edodes Sing., Auricularia auricula Underw., Grifola frondosa S. F. Gray and Ganoderma lucidum Karst. are preferable. Furthermore, rice embryo oil containing γ-oryzanol is contained as the active ingredient. The composition for oral ingestion includes the adiponectin secretion-promoting composition and the composition for oral ingestion is used for ameliorating obesity, ameliorating hypertension and lowering cholesterol. Amelioration of circulatory diseases such as arteriosclerosis and life style related diseases such as diabetes caused by the deterioration in the secretion of the adiponectin can be promoted.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
PURPOSE:A water-soluble silver complex having a killing action (antiviral and antimicrobial action) on viruses, bacteria, molds, etc. in humor of organisms having immune action and in an aqueous solution containing no immune protein. CONSTITUTION:A complex having a chemical composition shown by the formula I or formula II (M1 is Ag&lt;+&gt;; L1 is organic compound such as antibiotic, etc. containing S or S and N to be linked to M1 to form water-soluble silver complex; L2 is organic compound containing S or S and N to be linked to M to form water-soluble additional matter of metallic complex; m is molecular ratio of L1 to M1, and 2-10 number; ratio of n to o is molar ratio of L2 to M2, and o is 2-8 when n is 1) is used as a germicide. The complex does not lose its effect even in humor such as serum, etc. having immune action, shows high germicidal effect in a concentration of very small amount of silver, and yet, it can be prepared rapidly, simply at low cost. The additional matter of metallic complex in the formula II contributes to improvement of antimicrobial action, chemical stability, and toxicity of the silver complex.
The present invention relates to a method for treating a cancer having a protein kinase gene fused to a gene coding for a nuclear-envelop protein or a protein interacting with the nuclear envelop in a subject comprising administering to the subject a therapeutically effective of an arsenic compound, an inductor of type 1 IFNs and a tyrosine kinase inhibitor (TKI), as combined preparation. Indeed, inventors have validated the present invention with in vivo and in vitro models. Treatments started in mice with leukemic burden being &gt;3% (up to 90%) hCD45+CD7+ cells in the blood as detected by flow cytometry in individual tested mice. DASA (20mg/Kg, diluted in 80mM citric acid, pH2.1) was delivered using per os administration. ATO (5mg/Kg, diluted in TBS, pH7) and PolyI:PolyC (PIPC, 20mg/Kg diluted in PBS, SIGMA) were injected using intraperitoneal route. The time scale of drug delivery is indicated for every experiment performed. Mice were weighed every day of treatments, in order to ensure they were not losing too much weight and also to adjust the delivered drug doses. DASA+ATO+PIPC treated mice had a significantly prolonged survival compared to the other treatment conditions, showing major differences between results of treatment protocols. ATO combined with IFN-type 1 inducers and inhibitors of TK represents a powerful way for eradication of T-ALL cells that implicate high ABL1 activity and nuclear pore protein lesions.
NEW MATERIAL:1-Methyl-4,5-dihydroorotyl-histidyl-proline amide expressed by formula I or an acid addition salt thereof. USE:A remedy for central nervous diseases, especially exhibiting a more powerful antagonism to a pentobarbital anesthesia than a thyrotropin-releasing-hormone (TRH), etc. and having little side effect and high safety. PREPARATION:A compound expressed by formula II (X&lt;1&gt; is an optionally protected imino group) or a reactive thereof is condensed with a compound expressed by formula III (X&lt;2&gt; is an optionally protected imino group) or a salt thereof in a solvent such as tetrahydrofuran (THF), in some cases in the presence of a deacidifying agent (example; alkali metal hydroxide, etc.), preferably at -10-10 deg.C. Thereafter the protecting group thereof is eliminated, and the resultant product is converted into its acid addition salt if desired.
A medical management system. The burdensome task of medication logging is greatly reduced for a patient when compared to conventional methods to perform these tasks. Moreover, the invention allows for pharmaceutical supplier/providers and healthcare providers the ability better to manage, track, and trend the medication and products that must be provided to patients. This integrated ability allows for better management of the inventory of highly perishable and life-saving medications for chronically ill patients. The invention also allows for highly accurate communication between patients and other parties including his/her medical doctor, a pharmaceutical supplier/provider who provides medications and products for the patient, as well as the insurance provider providing medical insurance coverage for the patient. The system integrates embedded functionality that ensures that in the accidental event that a patient is prescribed tainted medication, the patient is warned of the taint in due time before self-administering the medication to avoid potentially contracting a disease or other ailment from the tainted medication. Patient medication is tracked and trending over the lifetime of the medication and the treatment period for the patient. Exceptions that outlay the trending of the patient&#39;s medication are identified and properly communicated, sometimes automatically, to a healthcare provider or medical doctor who treats the patient. The system is adaptable for use generally or to treat specific diseases, such as chronic diseases as hemophilia, diabetes, asthma, HIV, and other diseases requiring long term treatment and ongoing administration of medications and products.
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain a composition for dyeing bacterial plaques, which improves selective dyeability of a coloring matter for dyeing bacterial plaques, controls dyeing of unnecessary parts such as gingival, oral mucosa, lips visually detects bacterial plaques and is excellent in taste.  &lt;P&gt;SOLUTION: This composition for bacterial plaques comprises xylitol, spice, a surfactant and the coloring matter for dyeing bacterial plaques. The surfactant is a polyoxyethylene hardened castor oil in the composition for dyeing the bacterial plaques. The coloring matter for dyeing the bacterial plaques is selected from tar-based xanthine coloring matters in the composition for dyeing the bacterial plaques. The composition for dyeing the bacterial plaques is liquid.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
The object of the present invention is a new method and new products for the therapeutic use of cytokines. The method is based on the sequential administration of a component A (e.g. a biotinylated antibody) able to deliver onto a particular pathologic target a second component B (e.g. avidin), followed by a component able to bind the component B (component C) (e.g. biotin), conjugated with the cytokines. The method permits to increase the local concentration of the modified cytokines (C-cytokines) through the interaction with the &#39;artificial&#39; receptor B and to cause a local biologic response mediated by &#39;natural&#39; receptors.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a cosmetic having caring functions and makeup functions for skin.  &lt;P&gt;SOLUTION: The cosmetic is obtained by including (1) boron nitride and (2) a polymer having a phosphorylcholine residue. The polymer having the phosphorylcholine residue is preferably Polyquaternium 51 and/or Polyquaternium 61. At least one kind of the polymer having the phosphorylcholine residue is contained in such a state as to be coated on powder. The average particle diameter of the boron nitride is preferably 3-10 μm. Furthermore, hyaluronic acid and/or a salt thereof are preferably contained. The dosage form thereof is preferably the form of solid face powder.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To provide use of esterquat as sand repellent in a composition.  &lt;P&gt;SOLUTION: The esterquat generating sand-repelling action in the composition is used in the composition containing a cosmetic composition. The cosmetic composition is used e.g. for protecting the skin from ultraviolet light by topically applying the cosmetic composition having the sand-repelling action to the skin. The esterquat, being at least one kind of esterquat containing an alkanol amine imparting sand repelling action to the composition as a base, in which the acyl component is derived from (a) monocarboxylic acid, (b) dicarboxylic acid, (c) tricarboxylic acid or a mixture thereof is used in the composition.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
The present invention focuses upon a method for inhibiting bone resorption. This method involves administering a 5-lipoxygenase inhibitor to a subject in an amount inhibiting the effects of an osteoclast-stimulating factor. When the production of the osteoclast-stimulating factors such as PTH, PTHrp, IL-1, TNF, LT, 1,25(OH)2D3 or other factors which may stimulate the production of 5-LO metabolites via the 5-lipoxygenase pathway is inhibited, bone resorption markedly declines. The direct osteoclast-stimulating factors include leukotriene, peptidoleukotriene and 5-hydroxyeicosatetraenoic acid. Other factors yet to be identified or previously known may also be 5-lipoxygenase metabolites that stimulate bone resorption. While 5-lipoxygenase inhibitors may be substrate analogs or allosteric inhibitors, a substance which inhibits the activity of this enzyme may utilize other mechanisms (e.g., inhibition of 5-LO biosynthesis) and nevertheless function to inhibit bone resorption. Preferred inhibitors included NGDA, MK886 and ZM230,487. The best inhibitor thus far noted is ZM230,487. The inhibition of bone resorption is highly desirable with, for example, periodontal disease, osteoporosis, estrogen deficiency, Paget&#39;s disease, inflammatory bone loss, bone malignancy, hyperparathyroidism. Administering of a 5-lipoxygenase inhibitor may be enteral-when oral administration is desired, parenteral, when appropriate (preferably by vascular injection or infusion), or topical such as application to oral tissues to prevent bone loss due to periodontal disease. The preferred range of 5-lipoxygenase inhibitors administered is from 0.1 to 10 mg/kg body weight/day.
A hard-tissue repair composition comprising a paste (A) containing an inorganic powder of calcium phosphate, a polymerizable monomer mixture and a polymerization initiator and a paste (B) containing an inorganic powder of calcium phosphate, a polymerizable monomer mixture and a polymerization accelerator, wherein the content of the inorganic powder in each paste is 75-85 wt. % and each monomer mixture contains monomers represented by general formulae (1) and (2), the content of the monomer (1) accounting for 40-65 wt. % of the monomer mixture as a whole. The composition can well adhere to the bone and has a sufficient water resistance. As it generates little heat upon hardening, it is less detrimental to the patient&#39;s tissue. Furthermore, as the paste has an appropriate consistency, the supply unit of the invention facilitates homogeneous mixing of the pastes and application of the resultant mixture to the affected part. Thus this composition can be used not only as a bone cement but also as a filler for the defected part of the bone, a bone prosthesis, or an artificial bone.
PURPOSE:To obtain a whitening agent, containing lactic acids selected from lactic acid, alkaline earth metal lactates and nonmetallic compounds of the lactic acid in a specific concentration and capable of suppressing melanization and useful for preventing and treating pigmentation, such as liver-spot and sunburn. CONSTITUTION:A whitening agent containing lactic acids selected from lactic acid, alkali metal or alkaline earth metal lactates and nonmetallic compounds of the lactic acid in &gt;=5vol./vol.%, preferably 5.0-50vol./vol.%, especially 8.0-30 vol./vol.% concentration. Furthermore, unsaturated fatty acids are preferably contained therein. Lauroleic acid (C121), myristoleic acid (C141), pentadecenoic acid (C151), etc., can be cited as the unsaturated fatty acids. In use, pH of the lactic acids is 2.5-9.0, preferably 3.0-8.0 and the dose thereof for an adult per day is 0.1-500g. The active ingredient is used alone or physiologically active substances, nutriments, etc., are preferably used therewith in combination.
According to the present invention, a mixed non-liquid skin gel pack is a self-produced customized skin gel pack which is customized in real-time by a purchasing user. The mixed non-liquid skin gel pack comprises a base product. The base product comprises a base composition and a base storage part storing the base composition. The base composition contains a designated base component, is stored in a non-liquid state that can be liquefied, is converted into a liquid state by water in a designated temperature range, and then solidified under designated conditions to become a gel state and be molded into a skin gel pack detachably attached to a designated skin area. When N functional products, in which N (N&gt;=1) functional compositions containing designated functional components are stored in designated N functional storage parts, are prepared, the base composition is put into a designated mixing vessel, into which water within a designated temperature range is introduced, liquefied, and mixed with n (1&lt;=n&lt;=N) functional compositions that are designated by a purchase user from among N compositions corresponding to the N functional products and put into the mixing vessel before, during, or after the liquefaction. According to the present invention, a user can produce a customized skin gel pack optimized for his or her current skin condition.
Compositions and methods for treating cancer, particularly leukemia, using a cytotoxic composition comprising monocytes activated by [3-glucan. The monocytes are preferably incubated with the β-glucan and then processed to extract particles, such as microvesicles and exosomes from the treated monocytes to produce the cytotoxic composition. Preferably the cytotoxic composition comprises at least 50% exosomes having a size of 150 nm or less that are activated with β-glucan. Zymosan is the preferred β-glucan. The cytotoxic composition has an apoptosis effect. When a subject having cancer is treated according to preferred embodiments, the cytotoxic composition preferably induces a cytokine response in the subject&#39;s immune system. The combination of the cytotoxic composition and cytokine response are synergistic.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a hypoxia stress response promoter, to provide a method for screening the promoter, and to provide a method for screening an oxidative stress response promoter.  &lt;P&gt;SOLUTION: AGK2 ä2-cyano-3-[5-(2,5-dichlorophenyl)-2-furanyl]-N-5-quinolinyl-2-propenamide} is used as the hypoxia stress response promoter. Furthermore, the hypoxia stress response promoter is screened by measuring the activity of SIRT2 (a protein called also Sirtuin 2) in the presence of a test substance, and selecting a substance inhibiting the activity of the SIRT2. The test substance is further added into eEF1BδL gene, and a cell expressing a reporter gene linked to eEF1BδL target gene or an expression regulatory sequence of the target gene to measure the expression level of the target gene or reporter gene, and select a substance increasing the expression level. Thereby, the oxidative stress response promoter is screened.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a torpent capable of being readily formulated without having influence on function and shape of a preparation and an external preparation for skin containing the torpent.  &lt;P&gt;SOLUTION: The torpent comprises a glucose derivative, particularly a glucose derivative represented by general formula (I) (wherein R is a residue of 4-methoxyphenol, 4-carboxyphenol or 3-carboxyphenol). The external preparation for skin comprises the torpent. The external preparation for skin may further comprise an irritation causative agent [e.g. an oleagenous agent ingredient such as retinol and its derivative or an ultraviolet light absorber or an antiseptic agent] to the skin.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
A method for compiling, storing and organizing data, and gathering and reporting medical intelligence derived from patient-specific data. A patient&#39;s Minimum Data Set (“MDS”) data generated by health care facilities are merged with that patient&#39;s pharmacy data to create a comprehensive clinical/pharmacological data set for each patient. The data may first be encrypted to ensure patient privacy before being transmitted by the facility to a data repository via an electronic communication network. Upon receipt at the data repository, the data first must pass through a security screen. If the data is determined to be valid and virus-free, it is decrypted as necessary before being added to a data warehouse for use in a wide variety of therapeutic, statistical, and economic analyses. The data may be partially or completely “de-identified” to remove patient-identifying information so as to protect patient privacy.